RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 2, 2014
Released January 2014

Featuring interviews with Drs David H Ilson, Eric Van Cutsem, Eileen M O'Reilly and Herbert I Hurwitz. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although “non-CRC” gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials continuously lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update uses one-on-one discussion with leading GI oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES

    • Coordinate comprehensive biomarker analysis for patients diagnosed with advanced CRC, inclusive of broader RAS mutational assessments, and use this information to guide evidence-based care for these patients.
    • Effectively apply the results of practice-changing clinical research to the selection and sequencing of chemobiologic regimens for patients with metastatic CRC.
    • Consider clinical scenarios in which treatment rather than observation is warranted for patients with metastatic neuroendocrine tumors of the GI tract, and identify the optimal sequence of available systemic therapies for these patients.
    • Understand the importance of expanded RAS testing in selection of treatment for patients with advanced CRC.
    • Educate patients with metastatic gastroesophageal or pancreatic cancer regarding approved and novel treatment approaches and their associated risks and benefits.
    • Appreciate the recent FDA-approved indications for ramucirumab alone or in combination with paclitaxel for advanced gastric or GEJ cancer, and discern how this agent can be optimally integrated into clinical practice.
    • Communicate the benefits and risks of existing and emerging systemic interventions to patients with biliary tract cancer.
    • Counsel appropriately selected patients with GI cancer about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr IlsonAdvisory Committee: Amgen Inc, Celgene Corporation; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Speakers Bureau: Genentech BioOncology. Prof Van CutsemContracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi. Dr O’ReillyConsulting Agreements: Abbott Laboratories, Aduro Biotech, Amgen Inc, Astellas, Celgene Corporation, Celsion Corporation, Chugai Pharmaceutical Co Ltd, Cipla Limited, EntreMed Inc, Exelixis Inc, Genentech BioOncology, Gilead Sciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, IntegraGen, Jennerex Inc, Lilly, MedImmune Inc, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi, Silenseed Ltd, Vicus Therapeutics; Contracted Research: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Momenta Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Polaris Group, Roche Laboratories Inc, Vicus Therapeutics. Dr HurwitzAdvisory Committee and Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology, Genomic Health Inc, Lilly and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2015
    Expiration date: January 2016

Acknowledge and close

Listen to audio:
Gastrointestinal Cancer Update, Issue 2, 2014
Released January 2014

Featuring interviews with Drs David H Ilson, Eric Van Cutsem, Eileen M O'Reilly and Herbert I Hurwitz. (Text and Audio Content)

Read print: